瑞舒伐他汀依折麦布片(Ⅰ)治疗中国高胆固醇血症患者的成本-效果分析OA
Cost-effectiveness Analysis of Rosuvastatin Calcium and Ezetimibe Tablets(Ⅰ)in Patients with Hypercholesterolemia in China
目的 评估瑞舒伐他汀依折麦布片(Ⅰ)复方制剂(单片复方制剂)相比瑞舒伐他汀10 mg联合依折麦布10 mg(自由联合)在他汀类单药治疗后低密度脂蛋白胆固醇(LDL-C)无法达标的中国成人高胆固醇血症患者中的经济学价值.方法 基于医疗卫生体系视角构建 Markov 模型,模型包含 7 个健康状态:无事件、非致死性血运重建、非致死性心肌梗死(0~1 年,1 年以上)、非致死性缺血性卒中(0~1 年、1 年以上)及死亡.两组LDL-C降幅数据来源于一项中国多中心回顾性病例注册研究,临床获益通过LDL-C降幅差异推导主要不良心血管事件(MACE)风险差异.成本和效用值来源于文献.模拟周期为 1 年,模拟时限至中国预期寿命 79 岁;成本和效果的贴现率均为 5%.同时开展不同单片复方制剂的情境分析,即瑞舒伐他汀依折麦布(Ⅰ)复方制剂(每片含瑞舒伐他汀10 mg(按瑞舒伐他汀计)与依折麦布10 mg)和依折麦布阿托伐他汀钙片(Ⅱ)(每片含依折麦布10 mg与阿托伐他汀钙20 mg(以阿托伐他汀计)).为验证研究结果的不确定性,开展单因素和概率敏感性分析.结果 当单片复方制剂日均成本为3.10 元,自由联合日均成本为3.22 元时,单片复方制剂对比自由联合治疗的增量成本为-7457 元,增量质量调整生命年(QALYs)为0.177,单片复方制剂成本更低且疗效更好,具有绝对优势.情境分析结果显示增量成本为-1790 元,增量QALYs为 0.029,依折麦布阿托伐他汀钙片(Ⅱ)为绝对优势方案.单因素敏感性分析表明,单片复方制剂最小剂量的单位成本、每单位LDL-C水平降低带来心血管死亡率变化的比率、每单位 LDL-C 水平降低带来血运重建率变化的比率是影响研究结果的主要因素.概率敏感性分析显示,若以2024 年中国 1 倍人均国内生产总值(95 749 元)作为意愿支付阈值,单片复方制剂相比自由联合具有成本-效果的概率为100%,进一步验证了研究结果的稳健性.结论 对比自由联合,单片复方制剂在治疗经他汀单药治疗后 LDL-C 仍无法达标的中国成人高胆固醇血症患者中效果更好,成本更低,具有绝对优势.
Objective To assess the cost-effectiveness of Rosuvastatin Calcium and Ezetimibe Tablets(Single-Pill Combination therapy,SPC)versus free combination treatment(FCT,Rosuvastatin 10 mg/Ezetimibe 10 mg)in Chinese adult hypercholesterolemia patients whose LDL-C was not adequately controlled receiving statin monotherapy.Methods A Markov model was constructed from the healthcare system perspective,incorporating seven health states:event-free,non-fatal revascularization,non-fatal myocardial infarction(0~1 year,>1 year),non-fatal ischemic stroke(0~1 year,>1 year),and death.LDL-C reduction data for both groups were derived from a Chinese multicenter retrospective case registry study.Clinical benefits were extrapolated from the difference in LDL-C reduction to estimate the risk difference of major adverse cardiovascular events(MACE).Costs and utility values were sourced from literature.The model used a one-year cycle length and simulated outcomes up to the Chinese life expectancy of 79 years.Both costs and effects were discounted at 5%annually.Additionally,a scenario analysis was conducted on different SPCs,including Rosuvastatin Calcium and Ezetimibe Tablets(Ⅰ)(each tablet containing 10 mg of rosuvastatin[as rosuvastatin]and 10 mg of ezetimibe)and Ezetimibe and Atorvastatin Calcium Tablets(Ⅱ)(each tablet containing 10 mg of ezetimibe and 20 mg of atorvastatin calcium[as atorvastatin]).To validate the uncertainty of the study results,one-way and probabilistic sensitivity analyses(PSA)were performed.Results At daily costs of ¥3.10 for SPC versus ¥3.22 for FCT,SPC demonstrated clear dominance with cost savings of ¥7457 and a QALY gain of 0.177.In the scenario analysis,Rosuvastatin Calcium and Ezetimibe Tablets(Ⅰ)showed similar dominance versus Ezetimibe and Atorvastatin Calcium Tablets(Ⅱ)(cost savings:¥1790;QALY gain:0.029).One-way sensitivity analysis reveals that the main factors affecting the study results are the unit cost of the minimum dose of SPC,the ratio of cardiovascular mortality change per unit LDL-C level reduction,and the ratio of revascularization rate change per unit LDL-C level reduction.PSA shows that if China's 2024 per capita GDP(¥95,749)is used as the willingness-to-pay threshold,the probability of SPC being cost-effective compared to FCT is 100%,further validating the robustness of the study results.Conclusion Compared with FCT,SPC demonstrate superior efficacy and lower costs,emerging as the dominant treatment option for Chinese adult patients with hypercholesterolemia inadequately controlled with statin monotherapy.
彭晋;韩雨倍;赵明月;方宇;姜明欢
西安交通大学医学部药学院药事管理学系,西安 710061||西安交通大学药品安全与政策研究中心,西安 710061西安交通大学医学部药学院药事管理学系,西安 710061||西安交通大学药品安全与政策研究中心,西安 710061西安交通大学医学部药学院药事管理学系,西安 710061||西安交通大学药品安全与政策研究中心,西安 710061西安交通大学医学部药学院药事管理学系,西安 710061||西安交通大学药品安全与政策研究中心,西安 710061西安交通大学医学部药学院药事管理学系,西安 710061||西安交通大学药品安全与政策研究中心,西安 710061
医药卫生
瑞舒伐他汀依折麦布片(Ⅰ)高胆固醇血症成本-效果分析
Rosuvastatin Calcium and Ezetimibe TabletsHypercholesterolemiaCost-effectiveness analysis
《中国药物经济学》 2026 (6)
22-29,8
评论